Abstract
Introduction
Genetic analyses of families presenting with Alzheimer's dementia revealed that mutations in the amyloid precursor protein (APP) and presenilin 1 (PS1) protein were the cause of the disease for the affected kindred [1] [2] [3] [4] [5] [6] [7] . Overexpression of these mutant genes in transgenic mice showed that they enhance production of a 42-amino acid N-terminal peptide from APP, which enters the extracellular milieu [8] [9] [10] [11] [12] [13] . This A␤ peptide has amyloidogenic properties, forming multimers in a ␤-sheet structure [14] [15] [16] [17] . As enough of this material is produced, amyloid plaques form spontaneously and remain quite stable over time [18, 19] . Amyloidosis around the vasculature is also found in Alzheimer's disease (AD), and these plaques have been shown to grow more gradually with time [20] . This plaque production facilitates gliosis, and the role of microglia and astrocytes in AD is an area of intense investigation [21] [22] [23] [24] [25] . Microglia or macrophages become activated and can phagocytose A␤ [26, 27] ; however, more current work suggests that multiple activation states are found in the brain, and it may be possible to manipulate these states to promote A␤ clearance [28] [29] [30] [31] [32] [33] . Although amyloid plaques are the pathological end-point of aberrant A␤ production, a large number of studies have emerged suggesting that oligomeric forms of A␤ are the most pathogenic species [34] [35] [36] [37] [38] . A recent study demonstrated that dimeric A␤ species isolated from AD brain tissue impair synaptic plasticity and memory function when injected into normal rats [39] .
Although sporadic AD follows the same pathological roadmap as the familial cases, a definitive genetic cause has not been established [40, 41] . However, polymorphisms in the APOE (apolipoprotein E) gene have been identified as significant risk factors for lateonset AD (LOAD) [42] . The function of ApoE in AD has been extensively reviewed [43] . Briefly, this protein is produced by microglia and astrocytes in the brain and has a major impact on scavenging of the A␤ peptide from the extracellular space, fostering the clearance of amyloid [44, 45] [54, 55] . Tau pathology is found in a number of neurodegenerative diseases [56] [57] [58] [59] [55, 63] . Very recently, the first clinical trial with a putative tau aggregation inhibitor significantly slowed cognitive decline in AD patients and tau pathology was reduced [64] . These [73, 74] . But in addition to phosphorylation, other aspects of tau biology include folding [75] , nitration [76] , O-linked glycosylation, ubiquitination [77] and protease cleavage [78] . These [77, 82] and has anti-apoptotic properties. 
Substrate processing

Client degradation versus folding
Small molecules aptly named Hsp90 inhibitors have been generated and functionally force these clients to be degraded through the proteasome [83] [84] [85] [79, 80] [100] . Grp78 is now known to reduce amyloid production, further belying the importance of the ER chaperone system in AD [101] . CHIP also interacts with APP, and this is restricted to the ER and Golgi complex [102] . Another report suggests that the stress-activated protease, HtrA2, can regulate APP degradation at the ER, and when this protease is deleted, APP and consequently A␤ levels are elevated [103] . Although the ER chaperone family regulates APP processing, the cytosolic complement of chaperones, which includes the stress-inducible family, has also been linked to APP and amyloid biology [104] . Several protected these organisms from A␤-induced toxicity [106] . Interestingly, the critical pro-inflammatory cytokines, interleukin-1 and tumour necrosis factor-␣, facilitate the phosphorylation of small Hsps, perhaps suggesting that inflammation increases the Hsp27 chaperoning function [107] .
. For example, tau degradation was prevented by suppressing CHIP or Hsp90, but was enhanced by suppressing co-chaperones that promote re-folding or maintenance of Hsp90 clients, such as prostaglandin E synthase 3 (P23) or Cdc37 [80]. Hsp90 inhibitors also lead to increased activation of heat shock factor (HSF).
Chaperone expression
Hsp90 normally inhibits HSF1 by tethering it to the cytosol, preventing it from translocating to the nucleus. When Hsp90 levels are depleted by Hsp90 inhibition, HSF1 is released. Once it becomes phosphorylated, it trimerises and is able to enter the nucleus and begin transcribing genes containing heat shock elements (HSE)
In addition to small Hsps, cytosolic Hsp70 and Hsp90 were shown to inhibit early stages of amyloid aggregation [108] . Hsp70 was able to protect against intracellular A␤ as well [109] . More recently, administration of Hsp90 inhibitors to primary neurons prevented A␤-induced neurotoxicity, perhaps by increasing levels of Hsp70 and Hsp90 [110] ; however, it is also possible that this improved toxicity profile is due to reductions in aberrant tau by Hsp90 inhibition [80] , particularly in light of evidence demonstrating that tau knockout primary neurons are less susceptible to A␤-induced toxicity [111] [116] ; however, later reports suggested that presenilins were not tied to the UPR process [117] . Although this conflict is yet to be resolved, it is now known that PS1 forms aggresomes within the ER upon heat shock stress [118] . The functional consequence of these aggresomes remains unclear. [97, 121, 122] . Hsp27 preferentially binds to hyperphosphorylated tau as well as paired helical filamentous tau but not to non-phosphorylated tau [122] . The expression of another small Hsp, alphaB-crystallin has been found in glial inclusions of tauopathies [123] . Hsp27 also increases tau phosphorylation at Ser262, whereas alphaB-crystallin decreases phosphorylated tau and GSK-3␤ levels [124] . Interestingly, Hsp27 is cross-linked with tau in NFTs from AD brain [98] . Moreover, positive correlations have been found in the soluble protein levels from AD brain tissue between tau and molecular chaperones including Hsp27, Hsp40, Hsp90, alphaB-crystallin and CHIP [125] . [121] . Subsequent studies show that tau binds directly to Hsp70, and Bag1 has a role in this interaction [126, 127] . Taken together, these findings suggest that chaperones are necessary to maintain tau in a nonaggregated state, a consequence that may ultimately be deleterious for the brain. [128] . These Hsp90 inhibitors primarily facilitated the clearance of phospho-tau via proteasomal degradation, although lysosomal clearance also seemed to play a more minor role [79] . We also found that these inhibitors could reduce tau in transgenic tau mice. However, perhaps, more importantly, we identified a novel mechanism demonstrating that there are two pathways that can lead to opposing outcomes for tau biology with regard to Hsp90; some chaperones preserve tau, whereas others promote its degradation [80] . Furthermore, mutant, but not wild-type (WT) tau, is maintained in tauopathies by Hsp90; and the inhibition of Hsp90 leads to reductions in the pathogenicity of these mutant species [129] .
Chaperone regulation of the MAPT
Conversely, the levels of HSPs were inversely correlated with the levels of granulated tau oligomers, an intermediate of tau filaments. In a separate study, increased levels of Hsp70 and Hsp90 were found to promote tau solubility and MT binding in various cellular models
Other studies have provided new insights into the mechanisms employed by the chaperone network to handle abnormally accumulating tau. Initial studies from our group showed that pharmacologic inhibition of Hsp90 significantly reduced intracellular levels of the disease-associated phosphorylated tau species pS202/T205 and pS396/S404
CHIP has also been found to be critical for tau degradation. CHIP is found in tau lesions from AD and Pick's disease by immunohistochemistry [130] . CHIP also binds to and ubiquitinates tau directly, and this association is facilitated by Hsp70 [97] . This ubiquitination process preferentially occurs on exon 10 (ϩ) tau, the material that abnormally accumulates in a number of tauopathies [131] . Conversely, mice deficient in CHIP had significant accumulation of hyperphosphorylated tau species that did not aggregate and were ubiquitin-negative [77] . Biochemical analyses showed increased levels of CHIP and Hsp70 in AD, and CHIP levels were inversely proportional to sarkosyl-insoluble tau [132] . We also demonstrated that CHIP is the critical mediator of Hsp90 inhibitor-mediated tau reductions [80] . In aggregate, these studies suggest that ubiquitination may be critical for insoluble tau filament formation, and any clearance mechanisms of tau may be dependent on CHIP.
As these chaperone machines survey the cell, they come in contact with many different proteins, and we speculated as to whether these scaffolds might serve as a nexus for modifying proteins to act on tau. Akt, an oncogenic master kinase that can phosphorylate tau, is also elevated in AD [133] . We found that Akt is also a client of CHIP, and that this interaction is highly dependent on Hsp90 [81] Fig. 3 .
Conclusions
The field of chaperone biology continues to gain momentum because of the critical role that these proteins appear to be playing in a number of diseases. The intricacies of these proteinaceous machines are just beginning to be imagined. For AD, chaperones represent an entirely new aspect of disease biology, an aspect that may provide a common link to a great number of neurodegenerative disorders. However, within this complex system likely lies at least one specific therapeutic target that is yet to be identified for each of these diseases. By gaining insights into the mechanisms of chaperone biology, there is no doubt that these targets will come to light and a new generation of AD therapeutics will emerge. 
Fig. 3 Current model of tau processing through the chaperone network. Kinases such as MARK2 and Akt appear to operate in concert with Hsp90 to affect phosphorylation. MARK2 and Akt synergise to phosphorylate tau at KXGS motifs, which prevents tau degradation by the chaperone system. Other aberrant or misfolded tau is recognised by the Hsp40/Hsp70 complex. From here, tau can be either directly degraded by this complex or passed to Hsp90 to form an intermediate Hsp90 complex. Akt is associated with this complex. Here several courses can be taken based on the context: The Hsp90 complex can mature into a refolding machine and repair tau, or tau degradation can be facilitated, either out of necessity or Hsp90 inhibition. When Akt is present, tau degradation is impaired and thus it accumulates; however, when Akt is reduced by siRNA, tau degradation is enhanced. Akt is also a client of Hsp90 and thus is degraded in a fashion similar to tau.
